Mixed lineage kinase 3 is required for matrix metalloproteinase expression and invasion in ovarian cancer cells

Experimental Cell Research

Volumn 318, Issue 14, 2012, Pages 1641-1648

  Zhan, Yu ^a   Abi Saab, Widian F ^a   Modi, Nidhi ^a   Stewart, Amanda M ^a   Liu, Jinsong ^b   Chadee, Deborah N ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AP 1; Invasion; MAPK; MLK3; MMP; Ovarian cancer

Indexed keywords

COMPLEMENTARY DNA; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MITOGEN ACTIVATED PROTEIN KINASE; MIXED LINEAGE KINASE 3; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL IMMORTALIZATION; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ZYMOGRAPHY;

EID: 84862853607     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.05.002     Document Type: Article

References (37)

1. Dutta S., Wang F.Q., Phalen A., Fishman D.A. Biomarkers for ovarian cancer detection and therapy. Cancer Biol. Ther. 2010, 9:668-677.
2. Jarboe E.A., Folkins A.K., Drapkin R., Ince T.A., Agoston E.S., Crum C.P. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2009, 55:619.
3. Langdon S.P., Smyth J.F. Growth factors and ovarian cancer. Endocr. Relat. Cancer 1998, 5:283-291.
4. Shan W., Liu J. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 2009, 8:3107-3111.
5. Lok G.T., Chan D.W., Liu V.W., Hui W.W., Leung T.H., Yao K.M., Ngan H.Y. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One 2011, 6:e23790.
6. Steinmetz R., Wagoner H.A., Zeng P., Hammond J.R., Hannon T.S., Meyers J.L., Pescovitz O.H. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol. Endocrinol. 2004, 18:2570-2582.
7. Vivas-Mejia P., Benito J.M., Fernandez A., Han H.D., Mangala L., RodriguezAguayo C., ChavezReyes A., Lin Y.G., Carey M.S., Nick A.M., Stone R.L., Kim H.S., Claret F.X., Bornmann W., Hennessy B.T., Sanguino A., Peng Z., Sood A.K., LopezBerestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin. Cancer Res. 2010, 16:184-194.
8. Sieben N.L., Macropoulos P., Roemen G.M., Kolkman-Uljee S.M., Jan Fleuren G., Houmadi R., Diss T., Warren B., Al Adnani M., De Goeij A.P., Krausz T., Flanagan A.M. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 2004, 202:336-340.
9. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001, 81:807-869.
10. Gallo K.A., Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 2002, 3:663-672.
11. Sathyanarayana P., Barthwal M.K., Kundu C.N., Lane M.E., Bergmann A., Tzivion G., Rana A. Activation of the Drosophila MLK by ceramide reveals TNF-alpha and ceramide as agonists of mammalian MLK3. Mol. Cell 2002, 10:1527-1533.
12. Korchnak A.C., Zhan Y., Aguilar M.T., Chadee D.N. Cytokine-induced activation of mixed lineage kinase 3 requires TRAF2 and TRAF6. Cell. Signal. 2009, 21:1620-1625.
13. Chadee D.N., Kyriakis J.M. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat. Cell Biol. 2004, 6:770-776.
14. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 1995, 270:16483-16486.
15. Schmalfeldt B., Prechtel D., Harting K., Spathe K., Rutke S., Konik E., Fridman R., Berger U., Schmitt M., Kuhn W., Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 2001, 7:2396-2404.
16. Kobel M., Gradhand E., Zeng K., Schmitt W.D., Kriese K., Lantzsch T., Wolters M., Dittmer J., Strauss H.G., Thomssen C., Hauptmann S. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int. J. Gynecol. Pathol. 2006, 25:121-130.
17. Ozanne B.W., Spence H.J., McGarry L.C., Hennigan R.F. Transcription factors control invasion: AP-1 the first among equals. Oncogene 2007, 26:1-10.
18. Nishida Y., Kohno K., Kawamata T., Morimitsu K., Kuwano M., Miyakawa I. Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Gynecol. Oncol. 1995, 56:357-361.
19. Hasegawa H., Senga T., Ito S., Iwamoto T., Hamaguchi M. A role for AP-1 in matrix metalloproteinase production and invadopodia formation of v-Crk-transformed cells. Exp. Cell Res. 2009, 315:1384-1392.
20. Stack M.S., Ellerbroek S.M., Fishman D.A. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int. J. Oncol. 1998, 12:569-576.
21. Liu J., Yang G., Thompson-Lanza J.A., Glassman A., Hayes K., Patterson A., Marquez R.T., Auersperg N., Yu Y., Hahn W.C., Mills G.B., Bast R.C. A genetically defined model for human ovarian cancer. Cancer Res. 2004, 64:1655-1663.
22. Hartkamp J., Troppmair J., Rapp U.R. The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion. Cancer Res. 1999, 59:2195-2202.
23. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274:21491-21494.
24. Ala-aho R., Kahari V.M. Collagenases in cancer. Biochimie 2005, 87:273-286.
25. Chen J., Miller E.M., Gallo K.A. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells. Oncogene 2010.
26. Mishra P., Senthivinayagam S., Rangasamy V., Sondarva G., Rana B. Mixed lineage kinase-3/JNK1 axis promotes migration of human gastric cancer cells following gastrin stimulation. Mol. Endocrinol. 2010, 24:598-607.
27. Swenson-Fields K.I., Sandquist J.C., Rossol-Allison J., Blat I.C., Wennerberg K., Burridge K., Means A.R. MLK3 limits activated Galphaq signaling to Rho by binding to p63RhoGEF. Mol. Cell 2008, 32:43-56.
28. Nakayama N., Nakayama K., Yeasmin S., Ishibashi M., Katagiri A., Iida K., Fukumoto M., Miyazaki K. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br. J. Cancer 2008, 99:2020-2028.
29. Chadee D.N., Xu D., Hung G., Andalibi A., Lim D.J., Luo Z., Gutmann D.H., Kyriakis J.M. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc. Natl. Acad. Sci. USA 2006, 103:4463-4468.
30. Rana A., Gallo K., Godowski P., Hirai S., Ohno S., Zon L., Kyriakis J.M., Avruch J. The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. J. Biol. Chem. 1996, 271:19025-19028.
31. Rennefahrt U.E., Illert B., Kerkhoff E., Troppmair J., Rapp U.R. Constitutive JNK activation in NIH 3T3 fibroblasts induces a partially transformed phenotype. J. Biol. Chem. 2002, 277:29510-29518.
32. Schutte J., Minna J.D., Birrer M.J. Deregulated expression of human c-Jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc. Natl. Acad. Sci. USA 1989, 86:2257-2261.
33. Kim S., Oh J.H., Lee Y., Lee J., Cho K.H., Chung J.H. Induction of tissue inhibitor of matrix metalloproteinase-2 by cholesterol depletion leads to the conversion of proMMP-2 into active MMP-2 in human dermal fibroblasts. Exp. Mol. Med. 2010, 42:38-46.
34. Toth M., Chvyrkova I., Bernardo M.M., Hernandez-Barrantes S., Fridman R. Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem. Biophys. Res. Commun. 2003, 308:386-395.
35. Butler G.S., Butler M.J., Atkinson S.J., Will H., Tamura T., Schade van Westrum S., Crabbe T., Clements J., d'Ortho M.P., Murphy G. The TIMP2 membrane type 1 metalloproteinase receptor regulates the concentration and efficient activation of progelatinase A. A kinetic study. J. Biol. Chem. 1998, 273:871-880.
36. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2:657-672.
37. Cole E.T., Zhan Y., Abi Saab W.F., Korchnak A.C., Ashburner B.P., Chadee D.N. Mixed lineage kinase 3 negatively regulates IKK activity and enhances etoposide-induced cell death. Biochim. Biophys. Acta 2009, 1793:1811-1818.